Market Cap
$24.7B
BNTX
BioNTech SE
$96.56 ▼ -0.30%
Prev close $96.85Market cap$24.7B
ConsensusBuy
12-mo target$116.16 (+20.3%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10)29 New Institutional Positions19 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on BNTX right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (78%)
Inst. Holders
50 funds
Inst. Value
$3.4B
Inst. Activity
29 buys / 19 sells
Insider Activity
$0.00 buy / $69.2M sell
Insider Net $
-$69.2M
Social Sentiment
53° Neutral
SEC Reports
16
Press Releases
9
Price chart 30d -7.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 Insider
Sahin Ugur sold 32,000 shares
Chief Executive Officer @ $98.12 ($3.1M)
Sep 29, 2026 Insider
Sahin Ugur sold 34,000 shares
Chief Executive Officer @ $98.26 ($3.3M)
Sep 28, 2026 Insider
Sep 14, 2026 SEC Sahin Ugur sold 34,000 shares
Chief Executive Officer @ $98.47 ($3.3M)
BioNTech and OncoC4 reported updated Phase 3 data for gotistobart in squamous NSCLC, showing median overall survival of
6-K — Impact 7/10
BioNTech and OncoC4 announced positive median overall survival (OS) data from stage 1 of the PRESERVE-003 Phase 3 trial
Impact 7/10
Sep 14, 2026 announcement
Aug 28, 2026 SEC BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and
BioNTech announced termination of the Phase 2 trial (BNT122-01) of autogene cevumeran as monotherapy in resected colorec
6-K — Impact 6/10
BioNTech filed a 6-K press release announcing upcoming data presentations at the IASLC 2026 World Conference on Lung Can
6-K — Impact 4/10
Analyst ratings buy % -3.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
78% rate it Buy or better · 27 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 8, 2026 | BMO Capital | DOWNGRADE | Market Perform | 53% |
| Aug 31, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Aug 5, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Aug 5, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Jul 8, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| May 27, 2026 | UBS | UPGRADE | Buy | 55% |
| May 22, 2026 | Bernstein | INITIATE | Market Perform | 51% |
| May 6, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| May 6, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 15 | 6 | 0 | 0 | 78% | |
| Aug 1, 2026 | 6 | 16 | 6 | 0 | 0 | 79% | |
| Jul 1, 2026 | 6 | 16 | 6 | 0 | 0 | 79% | |
| Jun 1, 2026 | 6 | 15 | 5 | 0 | 0 | 81% | |
| May 1, 2026 | 6 | 15 | 5 | 0 | 0 | 81% | |
| Apr 1, 2026 | 6 | 15 | 6 | 0 | 0 | 78% | |
| Mar 1, 2026 | 7 | 16 | 5 | 0 | 0 | 82% | |
| Feb 1, 2026 | 7 | 17 | 4 | 0 | 0 | 86% |
Price targets
Where 20 covering analysts think BNTX trades over the next 12 months.
$116.16 +20.3% upside Strong Buy
Current$96.56 Low$73.40 Median$122.62 High$140.03 20 analysts
$73.40$140.03
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Social media sentiment mood +13.6%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
53°
Neutral
BearishNeutralBullish
Recent posts
BNTX meeting
▲ 1 · 💬 0· ⚡ 0.5
BioNTech ($BNTX) is arguably the most undervalued stock in the biotech sector today and i dont understand why
▲ 1 · 💬 6· ⚡ 0.5
$BNTX - what is happening here 68mins after opening? Any news or ideas?
▲ 1 · 💬 0· ⚡ 0.5
BNTX ASCO 2026 DD
▲ 1 · 💬 0· ⚡ 0.5
BNTX is about to go full send at ASCO and nobody’s talking about it 🚀🧬
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 3 bullish, 3 bearish, 3 mixed, 7 neutral · avg impact 5.3/10.Plus 9 press releases.
BULLISH6-K7/10
BioNTech and OncoC4 reported updated Phase 3 data for gotistobart in squamous NSCLC, showing median
Sep 14, 2026
BEARISH6-K6/10
BioNTech announced termination of the Phase 2 trial (BNT122-01) of autogene cevumeran as monotherapy
Aug 28, 2026
NEUTRAL6-K4/10
BioNTech filed a 6-K press release announcing upcoming data presentations at the IASLC 2026 World Co
Aug 20, 2026
MIXEDINST-CLUSTER5/10
BioNTech's 2026-Q2 institutional cluster shows a mixed picture: 5 buyers (led by a new $39.4M positi
Aug 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 16, 2026
Clinical Trial
HARE-40: HPV Anti-CD40 RNA vaccinE
Phase Phase 2 — COMPLETED
Sep 15, 2026
Clinical Trial
A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines
Phase Phase 2 — COMPLETED
Sep 14, 2026
announcement
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first
Sep 14, 2026
short_volume
Short Volume: BNTX — 58.5% short (0.3M / 0.5M)
Short: 302,887 | Exempt: 376 | TRF Vol: 517,918 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
Clinical Trial
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
Phase Phase 3 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.76 | $0.39–$1.35 | 730.6% | +0.0% | 3↑ 0↓ | $1.1B | 5 |
| Next Q | $-0.75 | $-2.19–$0.11 | -128.4% | +5.0% | 2↑ 1↓ | $0.5B | 5 |
| Current FY | $-4.65 | $-6.61–$-3.30 | -869.7% | +6.3% | 1↑ 6↓ | $1.8B | 9 |
| Next FY | $-4.91 | $-6.70–$-3.07 | -5.5% | -1.1% | 2↑ 4↓ | $1.8B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.757 | — |
| 7d ago | $0.757 | — |
| 30d ago | $0.757 | — |
| 60d ago | $0.657 | +0.100 |
| 90d ago | $0.657 | +0.100 |
Institutional ownership
Which big funds own BNTX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $3.4B total value (36,958,219 shares) as of 2026-Q2. Top holders: FMR, PRIMECAP, DODGE. Net buying activity: 29 institutions added/increased vs 19 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 7,571,805 | $704.6M | 20.5% | ADD +32.6% |
| PRIMECAP MANAGEMENT CO/CA/ | 3,772,031 | $351.0M | 10.2% | — |
| DODGE & COX | 3,677,591 | $342.2M | 9.9% | — |
| FLOSSBACH VON STORCH SE | 2,226,138 | $207.1M | 6.0% | TRIM -39.5% |
| BlackRock, Inc. | 1,854,966 | $172.6M | 5.0% | ADD +43.8% |
| Temasek Holdings (Private) Ltd | 1,506,027 | $140.1M | 4.1% | — |
| BNP PARIBAS FINANCIAL MARKETS | 1,319,517 | $122.8M | 3.6% | — |
| FIRST TRUST ADVISORS LP | 791,469 | $73.6M | 2.1% | — |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 744,200 | $69.2M | 2.0% | — |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 677,708 | $63.1M | 1.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | ADD | 5,709,240 | 7,571,805 | +32.6% | $704.6M |
| FLOSSBACH VON STORCH SE | TRIM | 3,680,315 | 2,226,138 | -39.5% | $207.1M |
| BAILLIE GIFFORD & CO | TRIM | 882,572 | 592,380 | -32.9% | $55.1M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 96,829 | 589,903 | +509.2% | $54.9M |
| BANK OF AMERICA CORP /DE/ | TRIM | 903,029 | 486,205 | -46.2% | $45.2M |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 93,455 | 463,163 | +395.6% | $43.1M |
| Assenagon Asset Management S.A. | NEW | — | 423,263 | — | $39.4M |
| D. E. Shaw & Co., Inc. | DOUBLED | 199,768 | 417,421 | +109.0% | $38.8M |
| MARSHALL WACE, LLP | ADD | 249,046 | 382,147 | +53.4% | $35.6M |
| CITADEL ADVISORS LLC | TRIM | 951,372 | 364,585 | -61.7% | $33.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
5 insiders, 28 transactions. Net -$69.2M — $0.00 bought, $69.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Sahin Ugur | Chief Executive Officer | SELL | 32,000 | $98.12 | $3.1M |
| Sep 29, 2026 | Sahin Ugur | Chief Executive Officer | SELL | 34,000 | $98.26 | $3.3M |
| Sep 28, 2026 | Sahin Ugur | Chief Executive Officer | SELL | 34,000 | $98.47 | $3.3M |
| Sep 25, 2026 | Sahin Ugur | Chief Executive Officer | SELL | 27,000 | $98.69 | $2.7M |
| Sep 24, 2026 | Sahin Ugur | Chief Executive Officer | SELL | 39,000 | $98.99 | $3.9M |
| Sep 23, 2026 | Sahin Ugur | Chief Executive Officer | SELL | 30,000 | $99.40 | $3.0M |
| Sep 22, 2026 | Sahin Ugur | Chief Executive Officer | SELL | 46,000 | $100.72 | $4.6M |
| Sep 21, 2026 | Sahin Ugur | Chief Executive Officer | SELL | 33,000 | $97.81 | $3.2M |
| Sep 18, 2026 | Sahin Ugur | Chief Executive Officer | SELL | 30,000 | $96.22 | $2.9M |
| Sep 17, 2026 | Sahin Ugur | Chief Executive Officer | SELL | 34,000 | $98.60 | $3.4M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for BNTX.
Shares short
2,322,764
Settlement Sep 15, 2026
Change vs prior
+0.9%
Semi-monthly cycle
Days to cover
2.6
At avg daily volume
Of shares outstanding
≈0.9%
Estimate — not % of float
All BNTX filing & press-release reports (25)
- 6-K reportSep 14, 2026
- PRESS-RELEASE reportSep 14, 2026
- 6-K reportAug 28, 2026
- 6-K reportAug 20, 2026
- INST-CLUSTER reportAug 11, 2026
- 6-K reportAug 4, 2026
- 6-K reportAug 3, 2026
- PRESS-RELEASE reportAug 3, 2026
- 6-K reportJul 29, 2026
- 6-K reportJun 8, 2026
- 6-K reportJun 1, 2026
- PRESS-RELEASE reportMay 30, 2026
- 6-K reportMay 22, 2026
- PRESS-RELEASE reportMay 22, 2026
- 6-K reportMay 15, 2026
- 6-K reportMay 7, 2026
- 6-K reportMay 5, 2026
- 6-K reportMay 5, 2026
- PRESS-RELEASE reportMay 5, 2026
- PRESS-RELEASE reportApr 21, 2026
- 6-K reportApr 13, 2026
- PRESS-RELEASE reportApr 11, 2026
- PRESS-RELEASE reportMar 24, 2026
- PRESS-RELEASE reportMar 10, 2026
- PRESS-RELEASE reportMar 10, 2026